Tin-117m somatostatin receptor binding compounds and methods
AssigneeSerene, LLC
InventorsNigel R. Stevenson, Jaime Simon, Gilbert R. Gonzales
Life of this patent
Estimating the term…
Abstract
Tin-117m somatostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analogue is also disclosed, as well as novel methods to produce the tin labeled analogues and antagonists.
Claims3
A method of forming tin-117m DOTA-TATE comprising reacting tin+2-117m with DOTA-TATE and, after the reacting step, oxidizing said tin+2-117m to tin+4-117m.
A method of forming tin-117m DOTA-TATE consisting essentially of reacting tin+2-117m with DOTA-TATE and, after the reacting step, oxidizing said tin+2-117m to tin+4-117m.
Dependencies are inferred from the claim text.